Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical

Animal Studies with Impressive Results

Global Cancer Technology, a San Diego, CA biotechnology company, has successfully completed
animal testing with GCT.GLIO.1, a PI3K selective inhibitor that can cross the blood brain barrier
and modulate immune cell function. The company will advance the compound to Phase 1 clinical
trials as a next step.

San Diego, CA July 08, 2022 --(PR.com)-- Global Cancer Technology, Inc. (GCT) announced today that
it has successfully conducted glioblastoma pre-clinical animal studies and is preparing for Phase 1 clinical
trials. The company has been advancing the selective inhibitor through laboratory and animal testing.
Glioblastoma is one of the most complex, deadly, and difficult to treat cancers. It is a challenging disease
with an average survival time of eight (8) months following diagnosis and less than 7% five-year survival
rate.

“These excellent results in cell culture demonstrate that GCT.GLIO.1 can induce cell arrest, increase
immune recognition for check point therapies and increase sensitivity to radiation. These are promising
effects in an animal model of glioblastoma,” stated Dr. Fonkem, a luminary neuro oncologist at Baylor
Scott & White. He continued, “Some of the findings from this research were presented at the AACR
annual meeting in New Orleans in March of 2022.”

“We found significant induction of PD-L1 in GL261 cells in culture and similar results on the Human
GBM cell line U251,” said Karen Newell Rogers, PhD, chief scientific consultant for GCT. Dr. Rogers is
also a professor and immunologist at Texas A&M University. “In fact, in several animals treated with
GCT.GLIO.1 and a checkpoint inhibitor, the tumor regressed. These animals remained tumor-free for as
long as 70 days after the tumor was implanted,” Dr. Newell further commented.

“The entire team at Global Cancer Technology is delighted with these pre-clinical results. We are looking
forward to entering a Phase 1 clinical trial once our remaining pre-clinical work is completed,” said John
Clark, CEO of GCT. He added, “There is a great deal of interest in PI3K inhibitors, and we are at the
forefront in developing this promising therapy to give hope to those inflicted with this deadly disease.”

About Global Cancer Technology

Global Cancer Technology (GCT) is a non-revenue emerging biopharmaceutical company that financially
operates as a medical technology holding company. GCT holds numerous patents and other assets
including licenses to commercialize nanoparticle technology for the treatment of COVID-19, cancer and
other diseases requiring targeted therapeutic delivery. In collaboration with highly acclaimed academic
institutions along with recognized industry leaders, GCT aims to make novel therapies available to
patients as quickly as possible. The company has already raised $1 million in a private placement and is
currently raising capital to enter a Phase 1 clinical trial with their compound GCT.GLIO.1

Statements in this news release may contain forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such

Page 1 of 4
PR.com Press Release Distribution Terms
statements may involve various risks and uncertainties, some of which may be discussed in the
Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale
by the FDA or successfully commercialized.

Page 2 of 4
PR.com Press Release Distribution Terms
Contact Information:
Global Cancer Technology
Loralyn Mears
804-539-2324
Contact via Email
globalcancertechnology.com
info@globalcancertechnology.com

Online Version of Press Release:

https://www.pr.com/press-release/864948

Page 3 of 4
PR.com Press Release Distribution Terms
 Page 4 of 4
PR.com Press Release Distribution Terms